Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23918692 | 0.85 | NR1I2 (0.35) | GPR84SLC2A1 | |
| SCHEMBL19231989 | 0.76 | GPR84 (0.38) | GPR84SLC2A1OPRM1SPHK1 | |
| SCHEMBL21755168 | 0.75 | OPRM1 (0.38) | GPR84SLC2A1OPRM1SPHK1 | |
| SCHEMBL21755084 | 0.74 | ACACB (0.36) | GPR84SLC2A1 | |
| SCHEMBL14357515 | 0.73 | LTB4R (0.39) | GPR84SLC2A1 | |
| SCHEMBL14357517 | 0.73 | TLR8 (0.44) | — | |
| SCHEMBL19055345 | 0.72 | GPR84 (0.38) | GPR84ADRB2OPRM1 | |
| SCHEMBL19231971 | 0.72 | SLC2A1 (0.36) | GPR84SLC2A1OPRM1SPHK1 | |
| SCHEMBL18661804 | 0.72 | SLC2A1 (0.39) | GPR84SLC2A1 | |
| SCHEMBL19965679 | 0.72 | GPR84 (0.35) | GPR84SLC2A1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210315872-A1 | COMPOUNDS AND METHODS FOR EP300 or CBP MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315872-A1 | COMPOUNDS AND METHODS FOR EP300 or CBP MODULATION AND INDICATIONS THEREFOR | EP300, CREBBP, HDAC11 | GPR84 2794/4885SLC2A1 3437/4885ADRB2 1054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.